Search
CureVac NV
CVACAdd to Watchlist
4.660USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.05BMarket Cap
9.59P/E TTM
More Details of CureVac NV Company
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
CureVac NV Info
Ticker SymbolCVAC
Company nameCureVac NV
IPO dateAug 14, 2020
CEOZehnder (Alexander)
Number of employees825
Security typeOrdinary Share
Fiscal year-endAug 14
AddressFriedrich-Miescher-Str. 15
CityTUEBINGEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code72076
Phone49707198830
Websitehttps://www.curevac.com/
Ticker SymbolCVAC
IPO dateAug 14, 2020
CEOZehnder (Alexander)
Company Executives of CureVac NV
Name
Name/Position
Position
Shareholding
Change
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+58.62%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+65.27%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+78.80%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
-100.00%
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Mr. Thaminda Ramanayake
Mr. Thaminda Ramanayake
Chief Business Officer, Member of the Management Board
Chief Business Officer, Member of the Management Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+58.62%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+65.27%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+78.80%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
-100.00%
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
FAQs
Who are the top five shareholders of CureVac NV?
The top five shareholders of CureVac NV are: Mr. Baron Jean Stephenne
How many institutions hold shares of CureVac NV (CVAC)?
As of 2025Q4, 242 institutions hold shares of CureVac NV, with a combined market value of approximately 23.52M, accounting for 11.47% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 45361.00.